Skip to main content

Table 2 Baseline Clinical Characteristics

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 

Number of participants, N (%)

Placebo(N = 102)

DNX 5 mg (N = 102)

DNX 10 mg (N = 103)

DNX 25 mg (N = 103)

DNX 35 mg (N = 102)

DNX 50 mg (N = 102)

Current smoker

39 (38)

40 (39)

37 (36)

35 (34)

38 (37)

36 (35)

Former smoker

63 (62)

62 (61)

66 (64)

68 (66)

64 (63)

66 (65)

SGRQ

 Q1 (I cough) most days a week or several days a week

80 (79)

86 (85)

74 (73)

80 (78)

78 (76)

82 (81)

 Q2 (I bring up phlegm) most days a week or several days a week

82 (81)

80 (79)

65 (64)

81 (79)

77 (75)

80 (79)

Chronic mucus hypersecretion (CMH)a

 CMH+

75 (74)

76 (75)

58 (57)

75 (74)

68 (67)

73 (72)

 CMH-

26 (26)

25 (25)

43 (43)

27 (26)

34 (33)

28 (28)

E-RS: COPD total score

  < 10

37 (36)

35 (34)

42 (41)

44 (43)

37 (36)

45 (44)

  ≥ 10

65 (64)

67 (66)

60 (59)

59 (57)

65 (64)

57 (56)

CAT score

  < 10

13 (13)

11 (11)

14 (14)

14 (14)

8 (8)

9 (9)

  ≥ 10

88 (87)

90 (89)

87 (86)

85 (86)

93 (92)

91 (91)

Exacerbation history:

  Moderate/severe

 1

15 (15)

19 (19)

26 (25)

17 (17)

11 (11)

22 (22)

  ≥ 2

87 (85)

83 (81)

76 (74)

86 (83)

91 (89)

80 (78)

Medications

 ICS + LABA + LAMA

39 (38)

44 (43)

45 (44)

43 (42)

39 (38)

40 (39)

 LABA + LAMA

24 (24)

23 (23)

30 (29)

20 (19)

21 (21)

34 (33)

 ICS + LABA

19 (19)

20 (20)

19 (18)

27 (26)

25 (25)

15 (15)

 LAMA

11 (11)

7 (7)

4 (4)

8 (8)

10 (10)

5 (5)

Inflammatory markers

 CRP (mg/L)

5.6 (9.4)

7.2 (23.8)

7.1 (15.1)

8.0 (17.5)

4.3 (5.0)

5.5 (8.1)

 Fibrinogen (g/L)

3.3 (0.9)

3.4 (1.0)

3.4 (0.9)

3.4 (0.8)

3.3 (0.8)

3.4 (0.8)

  1. aA subject is considered CMH+ if baseline SGRQ Q1 and Q2 = Most or several days a week.